Nusinersen
Product Description
QILU PHARMACEUTICAL CO., LTD.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
Categories
Specifications
QILU PHARMACEUTICAL CO., LTD.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
More Products from QILU PHARMACEUTICAL CO., LTD. (26)
-
Product bevacizumab
Bevacizumab is a humanized anti-VEGF-A mAb inhibiting tumor angiogenesis across multiple solid tumors. As the cornerstone anti-angiogenic agent with broad combination potential, it commands massive market volume with an established biosimilar competitive landscape. -
Product Bupivacaine
Bupivacaine utilizes proprietary DepoFoam technology to encapsulate bupivacaine within multivesicular liposomes, enabling sustained analgesia for up to 72 hours through a unique tri-phasic release mechanism involving initial burst, membrane diffusion, and particle erosion. This prolonged duration of action... -
Product daratumumab
Daratumumab is an anti-CD38 mAb for multiple myeloma across all lines of therapy. From first-line to relapsed settings, its subcutaneous Faspro formulation compresses infusion from hours to minutes, making it the absolute cornerstone of MM treatment. -
Product denosumab
Denosumab is a human anti-RANKL mAb; Prolia for osteoporosis and Xgeva for bone metastases. Its semiannual subcutaneous dosing offers superior compliance vs oral bisphosphonates, with dual-market positioning across orthopedics and oncology. -
Product Ipratropium Bromide and Salbutamol
Ipratropium Bromide and Salbutamol is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta2-adrenergic agonist) delivered via the soft mist inhaler. It provides superior relief of bronchospasm compared to either agent alone in COPD patients with persistent symptoms despite reg... -
Product Leuprorelin (3M, 6M)
Leuprorelin uses lyophilized microsphere technology with leuprolide acetate embedded in biodegradable PLGA polymer microcapsules. The active drug is released in two phases—diffusion and bioerosion—enabling 3-month or 6-month dosing intervals. As a GnRH agonist, it induces pituitary desensitization to reduc... -
Product ocrelizumab
Ocrelizumab is an anti-CD20 mAb and the only approved disease-modifying therapy for primary progressive multiple sclerosis (PPMS). With semiannual infusion and nearly 50% reduction in annualized relapse rate for RMS, it holds an unmatched position in neuroimmunology. -
Product Octreotide Acetate
Octreotide Scetate is a long-acting release formulation of octreotide acetate encapsulated in biodegradable PLGA microspheres, providing sustained release for approximately 28 days following intramuscular injection. It dramatically improves patient adherence and quality of life compared to multiple daily s... -
Product ofatumumab
Ofatumumab is an anti-CD20 mAb; Arzerra for CLL and Kesimpta for relapsing multiple sclerosis. Its monthly subcutaneous self-injection enables thorough B-cell depletion with significantly superior compliance vs intravenous CD20 alternatives. -
Product Paclitaxel
Paclitaxel is a Cremophor-free, albumin-bound paclitaxel formulation where paclitaxel is delivered in a suspension of albumin nanoparticles. It is administered as a 30-minute IV infusion without steroid or antihistamine premedication. It eliminates the need for Cremophor EL solvent, thereby removing the ri... -
Product Paliperidone Palmitate (1M, 3M)
Paliperidone Palmitate is a long-acting injectable (LAI) formulation using nanocrystal technology. It is supplied as prefilled syringes requiring no refrigeration or reconstitution, offering once-monthly (1M) and three-monthly (3M) dosing options for schizophrenia, which significantly improves treatment ad... -
Product panitumumab
Panitumumab is a fully human anti-EGFR mAb for RAS wild-type metastatic colorectal cancer. Its fully human sequence minimizes immunogenicity, with proven survival benefit in FOLFOX combination, representing a key precision therapy option in CRC.